Skip to NavigationSkip to content

Eli Lilly

Eli Lilly asks for a $24 million tax break for diabetes care facility expansion in Indianapolis

tpsdave/12019

Insulin manufacturer Eli Lilly has requested a $24 million tax break over the next 10 years as an investment into its diabetes care section.

The company itself is planning to invest $400 million in expanding its facility in Indianapolis. The expansion will create 100 new jobs and make sure 20 current jobs are retained. Michael O’Conner, the Eli Lilly Senior Director of State Government Affairs, presented this proposal to the Indianapolis City-County Council Metropolitan and Economic Development Committee this week.

Eli Lilly will limit insulin costs to $35 per month for patients in the US due to COVID-19

Photo by Alan Levine

Eli Lilly announced that it will limit out of pocket costs for insulin to $35 per month to offset the financial conditions created by the coronavirus.

This co-pay will cover both the insured and the uninsured but will not extend to Medicaid, Medicare or Medicare Part D patients. It will also include the Humalog injection.

Eli Lilly Diabetes President Mike Mason released a statement on Tuesday and said: “Too many people in the U.S. have lost their jobs because of the COVID-19 crisis, and we want to make sure no one goes without their Lilly insulin.

Lilly partners with Sitryx in $880m immunometabolism drug development deal

Eli Lilly and UK firm Sitryx have partnered up in a new drug development and commercialisation deal that could potentially be worth $880 million, it has been revealed.

The five-year deal gives Lilly the exclusive global rights to develop and market up to four of Sitryx’s preclinical compounds – including its two lead products – for the treatment of autoimmune diseases.

COVID-19: Gilead freezes compassionate access to remdesivir due to "overwhelming demand", BMS and Lilly delay new study launches

As national governments continue to ramp up measures to contain the ongoing COVID-19 coronavirus outbreak, so too are pharma and biotech organisations in the race to find a working treatment for the disease.  

Gilead has emerged at the front of the pack with its antiviral therapy remdesivir, which is currently proceeding through two late-stage clinical trials. But as a result of tentative success the drug has shown, the company has said it is facing “overwhelming demand” of compassionate use requests to receive the treatment.

Coronavirus forcing Eli Lilly employees to work from home

Eli Lilly is asking some of its employees to work from home to stop the spread of coronavirus on its Indianapolis campus.

The majority of workers who will stay home are office-based employees. People who work in research and manufacturing will continue to work at the company’s facilities.

Eli Lilly’s corporate communications director, Scott MacGregor, said in a statement that the company are “protecting the health and safety of our employees, and protecting our ability to make and supply safe medicines for patients who rely on them.

FDA advisory committee narrowly backs Eli Lilly's Cyramza combo for metastatic EGFR+ NSCLC

Eli Lilly’s Cyramza (ramucirumab) has edged closer to US approval after it scored a recommendation from the FDA’s Oncologic Drugs Advisory Committee (ODAC).

The committee voted 6 to 5 in favour of authorizing the VEGF receptor 2 agonist in the first-line treatment of adults with metastatic non-small cell lung cancer with activating EGFR mutations, when administered in combination with the EGFR-targeting tyrosine kinase inhibitor (TKI) erlotinib.

Eli Lilly's Trulicity approved in US to reduce cardiovascular events in type 2 diabetes patients

Eli Lilly’s Trulicity (duraglutide) has been awarded marketing authorisation from the FDA as a therapy to reduce major adverse cardiovascular events (MACE) in type 2 diabetes (T2D) patients with established cardiovascular (CV) disease or who exhibit multiple cardiovascular risk factors, it has been announced.

According to the manufacturer, this makes Trulicity the first and only type 2 diabetes therapy approved for this indication in primary and secondary prevention populations. It secured its first approval in the US back in 2014.

Lilly and Incyte's atopic dermatitis drug shows promise at Phase 3

Eli Lilly and Incyte have pulled back the curtain on Phase 3 data on their oral selective JAK inhibitor baricitinib as a treatment for moderate to severe atopic dermatitis in adult patients.

The findings showed that a clinically significant proportion of the trial’s participants taking either 1mg and 2mg doses of baricitinib achieved a change of at least 75% according to the Eczema Area and Severity Index (EASI) after 16 weeks of treatment, meeting the primary endpoint of the study.

Lilly & Incyte's Olumiant hits main goal in atopic dermatitis

Eli Lilly and Incyte have lifted the curtain on new Phase 3 data showing that their oral JAK inhibitor, showing that the candidate met its primary endpoint in the treatment of atopic dermatitis.

The data concerned Olumiant (baricitinib) in combination with topical corticosteroids (TCS) for the treatment of moderate to severe atopic dermatitis (AD) in adults who were inadequate responders, intolerant or had contraindication to treatment with cyclosporine.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches